A5081927196- Dementia and Cognitive Impairment Research
- Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Blood groups and transfusion
- Health Systems, Economic Evaluations, Quality of Life
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Healthcare Decision-Making and Restraints
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Autoimmune Bullous Skin Diseases
- Immunodeficiency and Autoimmune Disorders
- Acute Myeloid Leukemia Research
- Cancer, Hypoxia, and Metabolism
- Psychiatric care and mental health services
- Liver Disease Diagnosis and Treatment
- Digital Mental Health Interventions
- Multiple and Secondary Primary Cancers
- Schizophrenia research and treatment
- Treatment of Major Depression
- Cutaneous lymphoproliferative disorders research
- Wound Healing and Treatments
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Erythrocyte Function and Pathophysiology
- Cancer Treatment and Pharmacology
- Blood disorders and treatments
Otsuka (United States)
2019-2024
Otsuka Pharmaceutical (Spain)
2023-2024
Institute of Haematology and Blood Transfusion
2015
Pfizer (United States)
2003-2012
Instytut Hematologii i Transfuzjologi
1990-2007
Mayo Clinic
2003
Graco (United States)
2003
Agitation is a prevalent, distressing, and burdensome manifestation of Alzheimer dementia in need an efficacious, safe, well-tolerated treatment.
<b><i>Objective:</i></b> To assess the feasibility of using MRI measurements as a surrogate endpoint for disease progression in therapeutic trial AD. <b><i>Methods:</i></b> A total 362 patients with probable AD from 38 different centers participated portion 52-week randomized placebo-controlled milameline, muscarinic receptor agonist. The itself was not completed due to projected lack efficacy on interim analysis; however, arm study continued. Of subjects who underwent baseline study, 192...
Pregabalin is a novel compound in the development for treatment of anxiety disorders. The safety and efficacy pregabalin social disorder was evaluated double-blind, multicenter clinical trial which 135 patients were randomized to 10 weeks double-blind with either 150 mg/d, 600 or placebo. primary parameter change from baseline end point Liebowitz Social Anxiety Scale (LSAS) total score. Safety assessed through laboratory monitoring, recording spontaneously reported adverse events....
To assess the efficacy, safety, and tolerability of brexpiprazole in patients with agitation Alzheimer's dementia (AAD).Two 12-week, randomized, double-blind, placebo-controlled, parallel-arm studies (NCT01862640; NCT01922258).Study 1: 81 sites 7 countries. Study 2: 62 9 countries.Patients AAD (Study 433 randomized; 270 randomized) a care facility or community-based setting. Stable Alzheimer disease medications were permitted.Study 1 (fixed dose): 2 mg/day, placebo (1:1:1) for 12 weeks....
The aim of the study was to evaluate application vincristin or vinblastin in patients with chronic idiopathic thrombocytopenic purpura (ITP), resistant corticosteroids partial contraindication their application. Twenty-two were treated doses 2 and 10 mg, respectively. Eight these additionally administered prednisone an oral dose 0.5 mg/kg body mass (bm). Two-hour intravenous infusions drugs made once a week, at least three times. In every patient, platelet count evaluated before after...
Summary Administration of vinca alkaloids (VA) to chronic corticosteroid refractory immune thrombocytopenia (ITP) patients results in a temporary increase platelet count. The aim the study was evaluate efficacy preparing adult ITP for splenectomy as well compare costs this method with applying intravenous immunoglobulins. included 12 corticosteroids applied 3–144 months. were prepared average 3.0 (from 1 4) 2‐h infusions at 7 day intervals. In eight patients, vincristin used total dose 6 mg...
To assess the long-term safety, tolerability, and efficacy of brexpiprazole in patients with agitation associated dementia due to Alzheimer's disease (AD).
Background Major depressive disorder (MDD) is common worldwide and can be highly disabling. People with MDD face many barriers to treatment may not experience full symptom relief even when treated. Therefore, new modalities are needed for MDD. Digital therapeutics (DTx) provide people an additional option. Objective This study aimed describe a phase 3 remote, multicenter, randomized, masked, sham-controlled trial evaluating the efficacy of smartphone app–based DTx (CT-152) in adult...
Our study investigated two groups of adult patients with established diagnoses primary myelofibrosis (21 patients) and myelodysplastic syndromes (MDS) patients). The objective was to assess fetal hemoglobin (HbF) concentration investigate correlations organomegaly extramedullary hematopoiesis the level anemia blood transfusion requirement. In all patients, diagnosis confirmed by histopathological examination. Patients were ferrokinetics using 59Fe. percentage marrow sideroblasts assessed in...
<sec> <title>BACKGROUND</title> Major depressive disorder (MDD) is common worldwide and can be highly disabling. People with MDD face many barriers to treatment may not experience full symptom relief even when treated. Therefore, new modalities are needed for MDD. Digital therapeutics (DTx) provide people an additional option. </sec> <title>OBJECTIVE</title> This study aimed describe a phase 3 remote, multicenter, randomized, masked, sham-controlled trial evaluating the efficacy of...
Background A 12-week randomized controlled trial demonstrated that brexpiprazole is efficacious for treating agitation in patients with dementia due to Alzheimer's disease. Objective To assess the long-term safety and tolerability of treatment associated Methods This 12-week, active-treatment (oral 2 or 3 mg/day) extension ran from October 2018–September 2022 at 66 sites Europe/US. Patients disease a care facility/community-based setting who completed were eligible (N = 259 enrolled/analyzed...
The study presents results of B and T lymphocytes population analysis in patients with chronic lymphocytic leukaemia cells autoimmune haemolytic anaemia (CLL-B + AIHA). We evaluated the following groups patients: (1) newly recognized CLL-B co-existent AIHA (untreated), (2) after short-term treatment corticosteroids, (3) chemotherapy corticosteroids. control were made without AIHA. populations determination immunophenotype performed by means flow cytometry. analysed data obtained from 25...
Objective: Agitation in Alzheimer’s dementia (AAD) is prevalent, distressing, and burdensome. Medications for agitation are commonly prescribed off-label, although use hindered by safety tolerability concerns. This pooled analysis evaluates the of brexpiprazole patients with AAD. Methods: Data were from three Phase 3, 12-week, placebo-controlled trials (NCT01862640, NCT01922258, NCT03548584) (overall, dose). The primary objective each trial was to assess efficacy on agitation. Safety a...